21st-century use for surfactant?

Pediatrics

Volumn 123, Issue 1, 2009, Pages 173-174

  E Truog, William ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCINACTANT; LUNG SURFACTANT; SINAPULTIDE; UNCLASSIFIED DRUG;

DRUG DOSE REGIMEN; HUMAN; LOW BIRTH WEIGHT; LUNG DYSPLASIA; NEWBORN; NOTE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; PEDIATRICS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

HUMANS; PEDIATRICS; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 59449084737     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-3018     Document Type: Note

References (17)

1. Obladen M. History of surfactant up to 1980. Biol Neonate. 2005;87(4):308-316
2. Fujiwara T, Chida S, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980;1(8159):55-59
3. Halliday H. History of surfactant from 1980. Biol Neonate. 2005; 87(4):317-322
4. Lacaze-Masmonteil T. Expanded use of surfactant therapy in newborns. Clin Perinatol. 2007;34(1):179-189, ix
5. Engle WA; American Academy of Pediatrics, Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121(2):419-432
6. Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfos - ceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005; 115(4):1018-1029
7. Pandit P, Dunn M, Kelly E, Perlman M. Surfactant replacement in neonates with early chronic lung disease [published correction appears in Pediatrics. 1995;96(2 pt 1):359]. Pediatrics. 1995; 95(6):851-854
8. Katz L, Klein J. Repeat surfactant therapy for postsurfactant slump. J Perinatol. 2006;26(7):414-422
9. Bissinger R, Carlson C, Michel Y, Dooley C, Hulsey T, Jenkins D. Secondary surfactant administration in neonates with respiratory decompensation. J Perinatol. 2008;28(3):192-198
10. Merrill J, Ballard R, Cnaan A, et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res. 2004;56(6):918-926
11. Laughon M, Bose C, Moya F, et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dys-plasia. Pediatrics. 2009;123(1):89-96
12. Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely low-birth-weight infants. N Engl J Med. 1999; 340(25):1962-1968
13. Schmidt B, Roberts R, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-2121
14. Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation [published correction appears in N Engl J Med. 2007;357(14):1444-1445]. N Engl J Med. 2006;355(4):343-353
15. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007;357(19):1946-1955
16. Walsh M, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004;114(5):1305-1311
17. Hibbs AM, Walsh MC, Martin RJ, et al. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. J Pediatr. 2008;153(4): 525-529